What is the recommended management for headache in a patient with COVID-19?

Management of COVID-19-Related Headache

For acute COVID-19 headache, use paracetamol as first-line treatment, followed by NSAIDs (particularly dexketoprofen or ibuprofen) or triptans for refractory cases, with indomethacin reserved for treatment-resistant headaches. 1, 2, 3

Acute Headache Management

First-Line Treatment

• Paracetamol is the preferred initial agent for COVID-19-associated headache and fever, as it avoids theoretical concerns about NSAIDs during acute infection 1
• Continue paracetamol only while symptoms persist, not solely for temperature reduction 1
• Ensure adequate hydration (up to 2 liters daily) to prevent dehydration-related headache worsening 1

Second-Line Options for Moderate-to-Severe Headache

When paracetamol fails, the following agents demonstrate superior pain-freedom rates at 2 hours:

• Dexketoprofen achieves 58.8% pain freedom, making it the most effective NSAID option 2
• Triptans achieve 57.7% pain freedom and are appropriate for migraine-phenotype COVID headaches 2
• Ibuprofen achieves 54.3% pain freedom and is widely used (44% of patients require it) 2

The guideline recommendation to continue NSAIDs in patients already taking them regularly remains valid, though patients should report new fever or myalgia promptly 1

Refractory Acute Headache

• Indomethacin should be considered for headaches refractory to standard analgesics, NSAIDs, and triptans 3
• In a retrospective study, 97% of patients (36/37) experienced >50% headache relief by day 3 of indomethacin treatment, with 5 becoming completely asymptomatic by day 5 3
• This applies to both migraineurs and those without prior headache history 3

Short-Term Opioid Use

For distressing cough-related headache exacerbation:

• Consider codeine linctus, codeine phosphate tablets, or morphine sulfate oral solution for short-term symptom suppression 1
• This is appropriate when cough significantly worsens headache severity 1

Persistent Post-COVID Headache Management

Epidemiology and Phenotypes

• 50% of patients report persistent headache 12-15 months post-infection 4
• Persistent headaches are typically unilateral (40%), pulsating (38%), with phonophobia (74%), resembling migraine 4
• 10-20% of COVID-19 patients develop headache persisting beyond the acute phase 5, 6

Preventive Treatment Requirements

75% of patients with COVID-19 headache require preventive medication 2

First-Line Preventive Agent

• Amitriptyline is the most frequently used preventive (66% of patients) and achieves a 45.5% responder rate at the 50% reduction threshold 2
• Mirtazapine achieves a 50% responder rate but is used less frequently 2

Second-Line Options

• Anesthetic blockades are used in 18% of patients and achieve a 38.9% responder rate 2
• These are appropriate for semi-urgent procedures during the pandemic when telemedicine fails 1

Treatment-Resistant Cases

• OnabotulinumtoxinA achieves the highest 75% responder rate (18.2%) in refractory cases 2
• This represents the most effective option for severe, treatment-resistant persistent COVID headache 2

Dexamethasone for Prevention

• Dexamethasone administration during acute COVID-19 significantly reduces the likelihood of developing long-COVID headaches (52% vs 73%, p=0.029) 4
• This represents a critical preventive intervention during the acute phase 4
• However, guidelines urge caution with steroids due to immune suppression risks and potential increased viral infection risk 1
• Dexamethasone and betamethasone have shorter durations of immune suppression if steroids are deemed necessary 1

Clinical Approach Algorithm

Acute Phase (Days 1-10)

1. Start with paracetamol for mild-to-moderate headache 1
2. Escalate to dexketoprofen, ibuprofen, or triptans for moderate-to-severe or refractory headache 2
3. Consider indomethacin for treatment-resistant cases 3
4. Evaluate for dexamethasone if patient has risk factors for persistent headache (younger age, female sex, decreased CD4 T cells) 4

Persistent Phase (>4 weeks)

1. Initiate amitriptyline as first-line preventive 2
2. Consider anesthetic blockades if amitriptyline fails or is contraindicated 2
3. Reserve onabotulinumtoxinA for treatment-resistant cases requiring >75% reduction 2

Important Caveats

Telemedicine Priority

• All elective in-person visits should be suspended; use telemedicine as the first approach 1
• Telemedicine can be used to evaluate, initiate, and continue prescriptions for headache management 1
• Only semi-urgent procedures (such as anesthetic blockades for severe refractory headache) justify in-person visits 1

Risk Factors for Persistent Headache

Headache occurs more frequently in:

• Younger patients 4, 5
• Women (p=0.002) 4
• Those with previous primary headache or migraine history 5
• Patients with concomitant anosmia, ageusia, and myalgia 5
• Those with decreased CD4 T cell counts 4

Treatment Escalation Planning

• Put treatment escalation plans in place because COVID-19 patients may deteriorate rapidly 1
• Document advance care plans clearly, including do-not-attempt-resuscitation decisions 1
• This is critical as headache may signal worsening disease requiring urgent hospital admission 1